Alnylam Pharmaceuticals, Inc. (ALNY) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Alnylam Pharmaceuticals’s revenue went from $47M in fiscal 2016 to $3.7B in fiscal 2025, growth of about 62.4% a year.
Net income in fiscal 2025 was $314M, a net margin of 8.4%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $5.0B and net income $2.6B.
Free cash flow was $465M in fiscal 2025 and positive in 2 of the 10 years shown.
The diluted share count rose 57% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0B | $3.7B | $2.2B | $1.8B | $1.0B | $844M | $493M | $220M | $75M | $90M | $47M |
| Gross profit | $3.9B | $3.0B | $1.9B | $1.6B | $897M | $729M | $419M | $195M | $73M | $90M | — |
| Operating income | $978M | $502M | -$177M | -$282M | -$785M | -$709M | -$828M | -$939M | -$815M | -$500M | -$425M |
| Net income | $2.6B | $314M | -$278M | -$440M | -$1.1B | -$853M | -$858M | -$886M | -$761M | -$491M | -$410M |
| EPS (diluted) | $19.24 | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 | $-5.42 | $-4.79 |
| R&D | $1.6B | $1.3B | $1.1B | $1.0B | $883M | $792M | $655M | $655M | $505M | $391M | $382M |
| Revenue growth | — | +65.2% | +23.0% | +76.2% | +22.9% | +71.3% | +124.3% | +193.4% | −16.7% | +90.7% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $956M | $524M | -$8M | $104M | -$541M | -$642M | -$615M | -$278M | -$563M | -$383M | -$308M |
| Capital spending | -$150M | -$59M | -$34M | -$62M | -$72M | -$76M | -$70M | -$140M | -$127M | -$104M | -$65M |
| Free cash flow | $806M | $465M | -$43M | $42M | -$613M | -$718M | -$685M | -$419M | -$690M | -$487M | -$372M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $308M | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.9B | $2.7B | $2.4B | $2.2B | $2.4B | $1.8B | $1.5B | $1.1B | $1.7B | $618M |
| Debt | — | $1.3B | $1.3B | $1.3B | $1.3B | $322M | $521M | $304M | $30M | $30M | $150M |
| Equity | — | $789M | $67M | -$221M | -$158M | $588M | $1.0B | $1.4B | $1.3B | $1.8B | $920M |
| Total assets | — | $5.0B | $4.2B | $3.8B | $3.5B | $3.6B | $3.4B | $2.4B | $1.6B | $2.0B | $1.3B |
| Shares (diluted) | 138M | 135M | 128M | 125M | 122M | 118M | 115M | 109M | 101M | 91M | 86M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 77.4% | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | 85.0% | 88.6% | 97.6% | 100.0% | — |
| Operating margin | 19.5% | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | -556.2% | -900.3% |
| Net margin | 52.8% | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | -546.0% | -869.6% |
| FCF margin | 16.1% | 12.5% | -1.9% | 2.3% | -59.1% | -85.0% | -139.1% | -190.5% | -920.5% | -541.6% | -789.4% |
| ROIC | — | 23.5% | -9.6% | -20.5% | -53.4% | -61.5% | -42.6% | -42.6% | -48.3% | -27.8% | -39.7% |
| ROE | — | 39.8% | -414.6% | 199.5% | 714.9% | -145.0% | -84.5% | -61.6% | -58.5% | -27.8% | -44.6% |
Frequently asked questions
What is Alnylam Pharmaceuticals’s annual revenue?
$3.7B in fiscal 2025 and $5.0B over the twelve months to September 30, 2026.
How much profit does Alnylam Pharmaceuticals make?
Net income was $314M in fiscal 2025 (net margin 8.4%).
Is Alnylam Pharmaceuticals’s revenue growing?
Yes: revenue rose 65.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.